Ascenta, Ascentage Pharma Group Corp. deal

Ascenta granted Ascentage rights to develop and commercialize AT-101 and AT-406 in China and Taiwan. Ascentage also will have rights to AT-101 for all regions outside the U.S., Canada and Europe. Ascenta will receive an upfront payment and is eligible for milestones and royalties. ...